Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Elenbecestat with Itraconazole, Rifampin, Digoxin, or Donepezil
NCT02055703Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elenbecestat in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Pharmacokinetics of E2609 and metabolites and Pharmacokinetics of Digoxin. Started Jan 2014; status: completed.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02055703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055703.